Inspiremd Inc (NSPR) Stock Price, Quote & News

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid S...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 776 6804

Website: www.inspiremd.com

Address:

6303 Waterford District Drive, Suite 215, Miami, United States

ray1313 Jul. 4 at 9:29 AM

$NSPR no shark you messed up big here & everywhere else how much you down on this? Yikes!!!!!!!!!!!!!!

0 · Reply

focafoca99 Jul. 2 at 9:38 PM

$NSPR discussed a board resignation as Mr. Raymond W. Cohen steps down, effective July 1. https://www.rapidticker.com/news/nspr-sec-filing-e0fea6

1 · Reply

GiveHerTheDD Jul. 2 at 3:25 PM

$NSPR They were granted their SwitchGuard patent on 6-23-26 per uspto 👍🤞

0 · Reply

Onmywayup2021 Jul. 2 at 6:35 AM

$NSPR count me in in another 2-3 years, God willing

0 · Reply

Meterdoc Jul. 1 at 9:25 PM

$NSPR down 27% since I was called foolish. Calling this a cat turd for years.

3 · Reply

LoyalShark Jul. 1 at 7:22 PM

$NSPR It is what it is. Our CEO created this chart.

1 · Reply

HOBOWITHASHOTGUN Jul. 1 at 2:49 PM

$NSPR

1 · Reply

BioBuddha Jul. 1 at 9:31 AM

$NSPR usually Israeli micro caps are all fraud. This one I thought was going to be exception. I am still hopeful but hanging by a thread

0 · Reply

LoyalShark Jun. 30 at 1:37 PM

$NSPR Slosman needs to be fired. Complete loss of confidence in him. The market has lost its confidence in him The stock implodes and ??? This is a disaster.

0 · Reply

Threeways Jun. 30 at 12:58 PM

$NSPR with all the extra sales force sitting on their ass can they help propel international sales from $2.2 million to $3 million to help build confidence is the question. A big swing in international sales along FDA approvals may help swing this stock in August🤞🏻

1 · Reply

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 11, 2026, 8:00 AM EDT - 23 days ago

InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures

2026-06-08T12:07:53.000Z - 26 days ago

InspireMD enrolls first patient in CGUARDIANS III study

Jun 8, 2026, 8:00 AM EDT - 26 days ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures

May 13, 2026, 7:20 PM EDT - 7 weeks ago

InspireMD Transcript: Bank of America Global Healthcare Conference 2026

May 6, 2026, 4:05 PM EDT - 2 months ago

InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference

2026-05-05T11:00:54.000Z - 2 months ago

InspireMD price target lowered to $3 from $4 at Piper Sandler

2026-05-04T20:44:33.000Z - 2 months ago

InspireMD reports Q1 EPS (16c), consensus (18c)

May 4, 2026, 4:30 PM EDT - 2 months ago

InspireMD Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

InspireMD Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 2 months ago

InspireMD Quarterly report: Q1 2026

May 4, 2026, 4:05 PM EDT - 2 months ago

InspireMD Reports First Quarter 2026 Financial Results

May 4, 2026, 4:00 PM EDT - 2 months ago

InspireMD Slides: Investor presentation

2026-05-04T13:51:18.000Z - 2 months ago

InspireMD price target lowered to $4 from $5 at Lake Street

2026-05-04T13:50:39.000Z - 2 months ago

InspireMD withdrawing prior FY26 revenue guidance

2026-05-04T12:51:38.000Z - 2 months ago

InspireMD initiates voluntary U.S. recall of CGuard Prime 135 cm system

2026-05-01T20:11:00.000Z - 2 months ago

InspireMD announces FDA approval of IDE application for CGUARDIANS III study

May 1, 2026, 4:05 PM EDT - 2 months ago

InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System

May 1, 2026, 4:05 PM EDT - 2 months ago

InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System

Apr 27, 2026, 4:05 PM EDT - 2 months ago

InspireMD to Announce First Quarter 2026 Financial Results

Apr 22, 2026, 8:00 AM EDT - 2 months ago

InspireMD Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

InspireMD Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

InspireMD Proxy statement: Proxy filing

Apr 14, 2026, 12:45 PM EDT - 2 months ago

InspireMD Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 12:45 PM EDT - 2 months ago

InspireMD Slides: 25th Annual Needham Virtual Healthcare Conference

Apr 10, 2026, 8:00 AM EDT - 3 months ago

InspireMD Proxy statement: Proxy filing

Mar 31, 2026, 4:05 PM EDT - 3 months ago

InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference

Mar 18, 2026, 8:30 AM EDT - 3 months ago

InspireMD Earnings Call Transcript: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 3 months ago

InspireMD Annual report: Q4 2025

Mar 18, 2026, 8:30 AM EDT - 3 months ago

InspireMD Earnings release: Q4 2025

2026-03-18T11:11:13.000Z - 3 months ago

InspireMD reports Q4 EPS (14c), consensus (19c)

2026-03-18T11:10:33.000Z - 3 months ago

InspireMD sees FY26 revenue $13M-$15M, consensus $14.55M

Mar 18, 2026, 7:00 AM EDT - 3 months ago

InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 9, 2026, 9:00 AM EDT - 4 months ago

InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results

2026-02-12T15:11:44.000Z - 5 months ago

InspireMD participates in a conference call with Lake Street

2026-02-02T12:45:07.000Z - 5 months ago

InspireMD initiated with a Buy at Maxim

2026-01-20T14:05:16.000Z - 5 months ago

InspireMD reports inducement grants under Nasdaq listing rule

2026-01-12T14:20:11.000Z - 6 months ago

InspireMD announces publication of C-GUARDIANS trial

Jan 12, 2026, 9:00 AM EST - 6 months ago

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

Dec 3, 2025, 12:30 PM EST - 7 months ago

InspireMD Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-11-24T12:45:11.000Z - 7 months ago

InspireMD announces publication of CREST-2 data in NEJM

Nov 24, 2025, 7:30 AM EST - 7 months ago

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

2025-11-21T14:05:27.000Z - 8 months ago

InspireMD reports inducement grants under Nasdaq listing rule

Nov 19, 2025, 4:42 PM EST - 8 months ago

InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

Nov 4, 2025, 8:30 AM EST - 8 months ago

InspireMD Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

InspireMD Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

InspireMD Earnings release: Q3 2025

2025-11-04T12:15:34.000Z - 8 months ago

InspireMD reports Q3 EPS (17c) vs (16c) last year

Nov 4, 2025, 7:00 AM EST - 8 months ago

InspireMD Reports Third Quarter 2025 Financial Results

2025-11-03T12:42:01.000Z - 8 months ago

InspireMD names Peter Soukas as Chief Medical Officer

Nov 3, 2025, 7:30 AM EST - 8 months ago

InspireMD Names Peter A. Soukas, M.D.

Oct 21, 2025, 4:05 PM EDT - 9 months ago

InspireMD to Announce Third Quarter 2025 Financial Results

Sep 17, 2025, 8:00 AM EDT - 10 months ago

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

Sep 10, 2025, 10:00 AM EDT - 10 months ago

InspireMD Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 9:00 AM EDT - 11 months ago

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 8:00 AM EDT - 11 months ago

InspireMD Registration statement: Registration Filing

Aug 5, 2025, 8:30 AM EDT - 11 months ago

InspireMD Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 11 months ago

InspireMD Earnings release: Q2 2025

Aug 5, 2025, 8:30 AM EDT - 11 months ago

InspireMD Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 11 months ago

InspireMD Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 8:31 AM EDT - 1 year ago

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

Jul 31, 2025, 8:30 AM EDT - 1 year ago

InspireMD Announces Combined Financings of $58 Million

Jul 22, 2025, 7:00 AM EDT - 1 year ago

InspireMD to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 7:00 AM EDT - 1 year ago

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 24, 2025, 4:05 PM EDT - 1 year ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 13, 2025, 9:00 AM EDT - 1 year ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

Jun 3, 2025, 4:05 PM EDT - 1 year ago

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

May 14, 2025, 1:15 PM EDT - 1 year ago

InspireMD Transcript: Bank of America 2025 Healthcare Conference

May 9, 2025, 8:30 AM EDT - 1 year ago

InspireMD Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

InspireMD Earnings release: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

InspireMD Quarterly report: Q1 2025

May 9, 2025, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2025 Financial Results

Apr 30, 2025, 9:00 AM EDT - 1 year ago

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Apr 25, 2025, 9:00 AM EDT - 1 year ago

InspireMD to Announce First Quarter 2025 Financial Results

Apr 16, 2025, 8:00 AM EDT - 1 year ago

InspireMD Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

InspireMD Proxy statement: Proxy Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

InspireMD Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

InspireMD Registration statement: Registration Filing

Mar 26, 2025, 9:00 AM EDT - 1 year ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 12, 2025, 8:30 AM EDT - 1 year ago

InspireMD Earnings Call Transcript: Q4 2024

Mar 12, 2025, 8:30 AM EDT - 1 year ago

InspireMD Earnings release: Q4 2024

Mar 12, 2025, 8:30 AM EDT - 1 year ago

InspireMD Annual report: Q4 2024

Mar 12, 2025, 7:00 AM EDT - 1 year ago

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 1 year ago

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 7:00 AM EST - 1 year ago

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Dec 9, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Nov 25, 2024, 4:05 PM EST - 1 year ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 12, 2024, 8:30 AM EST - 1 year ago

InspireMD Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

InspireMD Earnings release: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

InspireMD Quarterly report: Q3 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Aug 6, 2024, 8:30 AM EDT - 2 years ago

InspireMD Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

InspireMD Quarterly report: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

InspireMD Earnings release: Q2 2024

Aug 6, 2024, 8:09 AM EDT - 2 years ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:00 AM EDT - 2 years ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Jul 30, 2024, 7:00 AM EDT - 2 years ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

May 28, 2024, 8:53 AM EDT - 2 years ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

InspireMD Earnings Call Transcript: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

InspireMD Quarterly report: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

InspireMD Earnings release: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 7:00 AM EDT - 2 years ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

Apr 18, 2024, 8:00 AM EDT - 2 years ago

InspireMD Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

InspireMD Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

InspireMD Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:59 AM EDT - 2 years ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 2 years ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 6, 2024, 8:30 AM EST - 2 years ago

InspireMD Earnings Call Transcript: Q4 2023

Mar 6, 2024, 8:30 AM EST - 2 years ago

InspireMD Earnings release: Q4 2023

Mar 6, 2024, 8:30 AM EST - 2 years ago

InspireMD Annual report: Q4 2023

Mar 6, 2024, 7:00 AM EST - 2 years ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 2 years ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

ray1313 Jul. 4 at 9:29 AM

$NSPR no shark you messed up big here & everywhere else how much you down on this? Yikes!!!!!!!!!!!!!!

0 · Reply

focafoca99 Jul. 2 at 9:38 PM

$NSPR discussed a board resignation as Mr. Raymond W. Cohen steps down, effective July 1. https://www.rapidticker.com/news/nspr-sec-filing-e0fea6

1 · Reply

GiveHerTheDD Jul. 2 at 3:25 PM

$NSPR They were granted their SwitchGuard patent on 6-23-26 per uspto 👍🤞

0 · Reply

Onmywayup2021 Jul. 2 at 6:35 AM

$NSPR count me in in another 2-3 years, God willing

0 · Reply

Meterdoc Jul. 1 at 9:25 PM

$NSPR down 27% since I was called foolish. Calling this a cat turd for years.

3 · Reply

LoyalShark Jul. 1 at 7:22 PM

$NSPR It is what it is. Our CEO created this chart.

1 · Reply

HOBOWITHASHOTGUN Jul. 1 at 2:49 PM

$NSPR

1 · Reply

BioBuddha Jul. 1 at 9:31 AM

$NSPR usually Israeli micro caps are all fraud. This one I thought was going to be exception. I am still hopeful but hanging by a thread

0 · Reply

LoyalShark Jun. 30 at 1:37 PM

$NSPR Slosman needs to be fired. Complete loss of confidence in him. The market has lost its confidence in him The stock implodes and ??? This is a disaster.

0 · Reply

Threeways Jun. 30 at 12:58 PM

1 · Reply

LoyalShark Jun. 29 at 2:20 PM

$NSPR While the rest of the market runs.....NSPR implodes. 1st in class product and a CEO that flat out messed up BIG.

2 · Reply

LoyalShark Jun. 29 at 2:18 PM

$NSPR EVeryday I wake and see what Slosman has done to this stock I want to vomit. Its not that he is fruadulent ...its is that he messed up big in not having the original delivery system approved at the same time the new one was approved. Like.....who would do that??? He left a 'one pint of failure disater ' in play and as it would work out....that scenario is exactly what happened.. We pay this guya a ton of money. For a screw. up as big as this one -- the guy needs to be fired. He screwed shareholders, his employees...and even his own bank account. 72 cents. Unbelievable.

1 · Reply

george1sun2003 Jun. 26 at 9:04 PM

$NSPR loyal shark doing well here he’s loses a lot of money

1 · Reply

arcuy Jun. 26 at 6:30 PM

$NSPR would be great if we also have a movement like $SLS

2 · Reply

Meterdoc Jun. 25 at 8:21 PM

$NSPR 🤭🤭🤭

0 · Reply

arcuy Jun. 25 at 7:31 PM

$NSPR Maybe it's time: a Rule 14a-8 shareholder proposal on InspireMD executive compensation for 2027 Just saying

0 · Reply

jensen146 Jun. 25 at 7:09 PM

$NSPR What is bad, this incompetent CEO was given a bonus, and he took it. I owned a private company with similiar income, we had nine employees not 129 employees. When times were tough there was no bonuses. The CEO should be fired. However, he is president of the board. I say the CEO and the president of the board should never be the same person in public company.

0 · Reply

Threeways Jun. 25 at 6:53 PM

$NSPR FYI the K & J warrants expire 20 trading days after announcement of TCAR and for the 4 quarters of Cguard sales trenches. With the expectation of those hitting back to back in August and September if the price doesn’t go above $1.38 we will be totally screwed being unexercised with only 3 quarters of cash runway left. 2 months left to get back or go broke

0 · Reply

Thespectator Jun. 25 at 6:31 PM

$NSPR lol beware when you see words like bargain and patience here 😂

1 · Reply

LoyalShark Jun. 25 at 5:50 PM

$NSPR One guy to thank for this disaster. Marvin Slosman, CEO Unbelievable yuo would have ONE PRODUCT and that ONE PRODUCT can not be sold because you were too stupid to get the delivery system that got the ONE PRODUCT you had through the approval process. INSTEAD you rely on a new delevery system to math with your ONE PRODUCT. I understand having them both apporved...I dont understand not having the tried and true delevery system approved. Totally TOTALLY destroyed shareholders. Now we get to do the HOW MUCH his incompetence cost us. The cost goes up every singel day. Fk Slosman.

1 · Reply

LoyalShark Jun. 25 at 4:46 PM

$NSPR Devestating what has happened to this investment. How does Slosman still have a job?

1 · Reply

zigsfrd Jun. 25 at 2:08 PM

$NSPR Would you rather be buying this right here or at 2 bucks? 72 % tute and insider ownership. How badly do you think these people want to F..k themselves. Be patient and wait for TCAR.

0 · Reply

Market Cap	32.74M
Revenue (ttm)	8.98M
Net Income (ttm)	-48.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-543.32%
Debt to Equity Ratio	0.00

Volume	160,200
Avg Vol	380,360
Day's Range	N/A - N/A
Shares Out	46.84M
Stochastic %K	51%
Beta	0.78
Analysts	Strong Sell
Price Target	$3.67